Identification of Genetic Mutations in Japanese Patients with Fructose-1, 6-Bisphosphatase Deficiency  by Kikawa, Yoshiharu et al.
Am. J. Hum. Genet. 61:852–861, 1997
Identiﬁcation of Genetic Mutations in Japanese Patients with
Fructose-1,6-Bisphosphatase Deﬁciency
Yoshiharu Kikawa,1 Manabu Inuzuka,2 Byun Young Jin,3 Satomi Kaji,3 Jun-ichi Koga,3
Yoshiki Yamamoto,3 Kazuro Fujisawa,1 Ikue Hata,1 Akio Nakai,1 Yosuke Shigematsu,1
Hideo Mizunuma,4 Akira Taketo,2 Mitsufumi Mayumi,1 and Masakatsu Sudo1
Departments of 1Pediatrics and 2Biochemistry, Fukui Medical School, Matsuoka, Fukui, Japan; 3Biotechnology Research Laboratories, JCR
Pharmaceuticals Co., Ltd., Takatsukadai, Nishi-ku, Kobe, Japan; and 4Department of Biochemistry, Akita University College of Allied Medical
Science, Akita, Japan
Summary Introduction
Fructose-1,6-bisphosphatase (FBPase) deﬁciency is an au- Fructose-1,6-biphosphatase (FBPase; E.C.3.1.3.11), a
tosomal recessive inherited disorder and may cause sudden key enzyme in the regulation of gluconeogenesis, cata-
unexpected infant death. We reported the ﬁrst case of mo- lyzes the hydrolysis of fructose-1,6-biphosphate to fruc-
lecular diagnosis of FBPase deﬁciency, using culturedmono- tose-6-phosphate and inorganic phosphate. FBPase de-
cytes as a source for FBPase mRNA. In the present study, ﬁciency is inherited as an autosomal recessive disorder
we conﬁrmed the presence of the same genetic mutation in mainly in the liver (Gitzelmann et al. 1995) and causes
this patient by amplifying genomic DNA. Molecular analy- life-threatening episodes of hypoglycemia and metabolic
sis was also performed to diagnose another 12 Japanese acidosis in newborn infants or young children (Emery
patients with FBPase deﬁciency. Four mutations responsible et al. 1988). Excretion of glycerol in urine is considered
for FBPase deﬁciency were identiﬁed in 10 patients from 8 the main abnormality observed in urine organic-acid
unrelated families among a total of 13 patients from 11 analysis of patients with FBPase deﬁciency (Burlina et
unrelated families; no mutation was found in the remaining al. 1990). Furthermore, administration of exogenous
3 patients from 3 unrelated families. The identiﬁed muta- glycerol provokes a response such as hypoglycemia,
tions included the mutation reported earlier, with an inser- which is quite similar to that observed after fructose
tion of one G residue at base 961 in exon 7 (960/961insG) administration (Gitzelmann et al. 1995). Hence, the use
(10 alleles, including 2 alleles in the Japanese family from of glycerol for therapeutic purposes can be potentially
our previous report [46% of the 22 mutant alleles]), and fatal. As a rule, the ﬁrst child with the disease dies or
three novel mutations—a GrA transition at base 490 in suffers more than the following children, who usually
exon 4 (G164S) (3 alleles [14%]), a CrA transversion at beneﬁt from the experience gained, by parents and phy-
base 530 in exon 4 (A177D) (1 allele [4%]), and a GrT sicians, with the ﬁrst child. Once the diagnosis is estab-
transversion at base 88 in exon 1 (E30X) (2 alleles [9%]). lished, treatment of FBPase deﬁciency is simple and
FBPase proteins with G164S or A177D mutations were prognosis is excellent. Therefore, carrier detection of
enzymatically inactive when puriﬁed from E. coli. Another FBPase deﬁciency is important for the prevention of sud-
new mutation, a TrC transition at base 974 in exon 7 den unexpected infant death caused by FBPase deﬁciency
(V325A), was found in the same allele with the G164S (Emery et al. 1988). However, a reliable method to iden-
mutation in one family (one allele) but was not responsible tify such carriers is not available, although enzymatic
for FBPase deﬁciency. Our results indicate that the insertion assay of FBPase in cultured monocytes or leukocytes has
of one G residue at base 961was associated with a preferen- been used successfully for this purpose (Ito et al. 1984;
tial disease-causing alternation in 13 Japanese patients. Our Kikawa et al. 1993). In this regard, the diagnosis of
results also indicate accurate carrier detection in eight fami- FBPase deﬁciency in leukocytes has been encountered
lies (73%) of 11 Japanese patients with FBPase deﬁciency, by several difﬁculties, in part because of the low activity
in whom mutations in both alleles were identiﬁed. of the enzyme in leukocytes (Gitzelmann et al. 1995).
Moreover, there seem to be at least two phenotypes of
FBPase deﬁciency. The ﬁrst involves deﬁciency of the
enzyme in the liver and leukocytes, whereas in the other
only the liver enzyme is affected (Bu¨hrdel et al. 1990;
Shin 1993; Besley et al. 1994). Therefore, enzyme assayReceived April 11, 1997; accepted for publication July 15, 1997.
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single-copy gene located on chromosome bands 9q22.2- DNA was performed in the other ﬁve patients (patients
2, and 8–11). Monocytes and lymphocytes were pre-q22.3. The human FBPase transcript unit spans 31 kb
and consists of seven exons. However, analysis of geno- pared as reported elsewhere (Kikawa et al. 1993). In
brief, monocytes were cultured for cDNA analysis withmic DNA in two patients with FBPase deﬁciency did
not show any mutation resulting in the synthesis of an 1 mM 1,25(OH)2D3 (Wako Chemicals) under 5% CO2
in air for 4 d. The lymphocytes were used for genomicabnormal protein (El-Maghrabi et al. 1995). We have
recently shown that, as a source alternative to liver sam- DNA analysis.
ples, monocytes can be used for mRNA encoding FBPase
Isolation of RNA and Genomic DNA, PCR(Kikawa et al. 1994), and we also have identiﬁed homo-
Ampliﬁcation, Sequencing, and Restriction Analysiszygosity for an insertion of one G residue at base 961
in a Japanese patient with FBPase deﬁciency (Kikawa et Total RNA was isolated, by Isozen (Wako Chemi-
cals), from cultured monocytes. Double-strand cDNAal. 1995). Our report seems to be the only study that
has detected a mutation responsible for FBPase deﬁ- was prepared as described elsewhere (Kikawa et al.
1994). The primer set 1F and 4R (listed in table 2) ofciency. Since genomic DNA sequencing is now available,
we analyzed the genomic DNA from the same patient complementary human FBPase cDNA permitted ampli-
ﬁcation of the coding sequence. Genomic DNA was iso-reported in our previous study, as well as those of her
parents. We conﬁrmed our earlier results obtained by lated from lymphocytes by standard methods (Maniatis
et al. 1989). The promoter and exons 1–7 of the FBPaseuse of mRNA from cultured monocytes. We have also
identiﬁed mutations responsible for the loss or decrease gene were PCR ampliﬁed from genomic DNA on eight
DNA fragments. The primers for PCR and the proce-of FBPase enzyme activities in 9 of 12 other Japanese
FBPase-deﬁcient patients, by analyzing genomic DNA dures for ampliﬁcation of genomic DNA were similar
to those described by El-Maghrabi et al. (1995). Theand cDNA. These mutations include three new types
responsible for FBPase deﬁciency. In the present study, PCR products from FBPase cDNA or genomic DNA
were separated on electrophoresis on a 1% (w/v) agarosewe report that the insertion of one G residue at base 961
is the most common mutation of FBPase gene among 13 gel and were extracted from the gel by use of the Jetsorb
kit (Genomed). The PCR products were sequenced byJapanese patients with FBPase deﬁciency (including the
patient from our previous report). This ﬁnding should ﬂuorescent-dye terminator–cycle sequencing after being
subcloned into Bluescript plasmid vector (Novagen). Al-be important for DNA-based diagnosis of carriers of
FBPase deﬁciency. ternatively, the PCR products were directly sequenced
by use of an automated DNA sequencer (model 373A;
Applied Biosystems). The sequencing primers for humanPatients and Methods
FBPase cDNA are listed in table 2. All mutations were
Patients conﬁrmed by sequencing after the subcloning. Primers
for PCR ampliﬁcation and M13 universal primers wereMolecular analysis was performed in 13 Japanese pa-
tients with FBPase deﬁciency who were from 11 unre- also used for sequencing.
lated families. We also recruited 11 carriers or healthy
PCR-SSCP Analysis and Restriction Analysisfamily members for molecular analysis, from 3 of the
11 families. The diagnosis of FBPase deﬁciency was es- The insertion of one G residue at base 961 does not
cause any change in restriction-enzyme sites. SSCP anal-tablished on the basis of the lack or presence of õ10%
of the normal level of FBPase activity in monocytes or ysis of PCR fragments containing the G insertion was
performed to detect both the insertion of one G residueliver tissue samples. Clinical details of some of these
patients have been reported elsewhere (Kinugasa et al. at base 961 and the TrC transition at base 974, ac-
cording to Orita et al.’s (1989) method with minor mod-1979; Ito et al. 1984; Nagai et al. 1992; Nakai et al;
1993; Kikawa et al. 1995). Results of analysis of cDNA iﬁcations. In brief, PCR was performed by use of the
forward primer 5F and the reverse primer 5R (listed atfrom patient 1 have been reported in detail elsewhere,
as the ﬁrst case of molecular analysis of a family with table 2). The PCR mixture in 20 ml of total volume
contained 2 pmol of each unlabeled primer, 4 nmol ofFBPase deﬁciency (Kikawa et al. 1995). Patients 4a and
4b were sisters, and patients 5a and 5b were brothers. each of the four deoxynucleotide triphosphates, 2 ml of
PCR product containing the insertion of G961, and 0.5Parents of patients 1, parents andmaternal grandparents
of patients 4a and 4b, and siblings and parents of patient U of Taq DNA polymerase. The PCR condition was 2
min at 94C (for denaturing), followed by 30 cycles of7 were also included in this study. The clinical proﬁles
of the 13 patients are summarized in table 1. All patients 30 s at 94C, 30 s at 60C, and 2 min at 72C. A 1-ml
portion of the reaction mixture was mixed with 9 ml ofexperienced recurrent attacks of metabolic acidosis and
hypoglycemia. Eight patients (patients 1, 3, 4a, 4b, 5a, SSCP loading buffer (95% formamide, 10 mM NaOH,
0.05% bromophenol blue, and 0.05% xylene cyanol)5b, 6, and 7) were analyzed both at the cDNA and the
genomic DNA levels, whereas only analysis of genomic and was heated at 95C for 2 min; 2 ml of sample were
/ 9a38$$oc05 09-15-97 13:16:27 ajhgal UC-AJHG
854 Am. J. Hum. Genet. 61:852–861, 1997
Table 1
Clinical Summary of 13 Japanese Patients with FBPase Deﬁciency
Age at First Age at First Symptom
Patient (Gender) Consanguinitya Symptom Diagnosis or Sign
1 (F) / 1 d 10 years Vomiting
2 (F) 0 11 mo 4 years Vomiting
3 (F) 0 1 year 16 years Drowsiness
4a (F) 0 16 mo 18 mo Vomiting
4b (F) 0 2 d 11 days Tachypnea
5a (M) 0 4 years 7 years Vomiting
5b (M) 0 4 years 4 years Drowsiness
6 (M) 0 8 mo 3 years Vomiting
7 (F) 0 Infancy 2 years Tachypnea
8 (F) / 1 year 1 year Vomiting
9 (M) 0 Dead at 1st d of life Tachypnea
10 (F) / Unknown 21 mo Hepatomegaly
11 (M) 0 4 years 5 years Vomiting
a / Å Presence of consanguinity; and 0 Å absence of consanguinity.
loaded onto an SSCP gel. Electrophoresis was performed ampliﬁcation of exon 1 were similar to those described
above. The PCR product was a 313-bp fragment. Re-at 35 W for 3 h at 20C.
The GrA transition at base 490 in exon 4 and the striction digests of all the PCR products were analyzed
on 10% polyacrylamide gel and electrophoresed in 1CrA transversion at base 530 in exon 4 create a new
AluI endonuclease restriction site, GGCTrAGCT, and 1 Tris borate–EDTA buffer for 1 h at 100 V. After
electrophoresis, the DNA bands were detected by Fluor-a loss of a NcoI endonuclease restriction site, CCATG-
GrACATGG, respectively. Primer sets and PCR condi- Imager (Molecular Dynamics) after being stained with
SYBERGreen I (Takara).tions for ampliﬁcation of exon 4 were similar to those
described above. The PCR product was a 281-bp frag-
In Vitro Mutagenesis and Expression of FBPase cDNAment. The GrT transversion at base 88 in exon 1 intro-
duces a new MaeI endonuclease restriction site, Among the ﬁve types of mutant clones, the clone with
one G residue insertion at 961 has already been con-CGAGrCTAG. The primer sets and PCR conditions for
Table 2
Primers for FBPase cDNA, SSCP Analysis, and In Vitro Mutagenesis
Primer Type Sequence Position in cDNA
For PCR ampliﬁcation:
1F Sense 5-CCCCGCGCTCTACCCGGTTCA-3 024–4
4R Antisense 5-TGTGTGAGACAAAAGGTCCA-3 1056–1075
For sequencing:
2F Sense 5-ACGTGTGTTCTCGTGTC-3 274–290
3F Sense 5-AGCCGGCTACGCACTGTAT-3 486–504
4F Sense 5-CAGATAATTCAGCTCCTTATGG-3 704–725
1R Antisense 5-CATGTTCATAACCAGGT-3 239–255
2R Antisense 5-GCAGTTGACCCCACAGTCCAT-3 532–552
3R Antisense 5-CACCATGGAGCCCACATACC-3 730–750
For SSCP analysis:
5F Sense 5-CCCGGTCTTGTTTTCCAGCTG-3 Intron 6–Exon 7
5R Antisense 5-GCAGAGTGCTTCTCATACACC-3 Exon 7
For in-vitro mutagenesis:
Mutagenic primer for
the G164S mutation 5-GTGCGTAGCTGGCTGCCACC-3 480–499
Mutagenic primer for
the A177D mutation 5-CAGTCCATGTCAAGGACCAG-3 520–539
Selection primer 5-CGTTGTTGCCATTGCCGCGGGCATCGTGGTGTC-3
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ﬁrmed as expressing no FBPase activity (Kikawa et al. mate their purity and size and were photospectromet-
rically evaluated for FBPase activity, as reported else-1995). The clone with the E30X mutation is expected
to result in premature termination, with approximately where (Mizunuma and Tashima 1986). One unit of
enzyme activity represented the amount that catalyzedone-twelfth of the length of normal FBPase protein with
337 amino acid residues. Therefore, only the effects of the hydrolysis of 1 nmol of fructose-1,6-biphosphate/
min. Speciﬁc activity was deﬁned as units per milligramthe G164S, A177D, and V325A mutations on FBPase
activity were tested. One of the 22 alleles harbored both of puriﬁed recombinant FBPase protein. In order to re-
move AMP contaminating either the solutions or thethe G164S and the V325A mutations A chimeric clone
with only the V325S mutation was prepared for exami- enzymes used for fructose-1,6-biphosphate assay, 0.1
unit of AMP deaminase was added to the assay mixture,nation of the pathogenicity of the V325A mutation. The
clone with both the G164S and the V325A mutations as since FBPase shows a high sensitivity to allosteric inhibi-
tion by AMP (Mizunuma and Tashima 1986).well as the normal clone, were cut by restriction enzyme
ApaI, at bases 924–927, and the ﬁrst part of the normal
SDS-PAGE and Western Blotting Analysisclone and the latter part of the mutant clone were li-
SDS-PAGE and western blotting of FBPase proteingated. This chimeric clone with only the V325S muta-
were performed by use of the methods described pre-tion, the site-speciﬁc mutagenated clone with the G164S
viously by Mizunuma and Tashima (1986). Antiseramutation, and a clone with A177D mutation were ex-
against puriﬁed recombinant human liver FBPase werepressed. The wild-type human liver cDNA (Kikawa et
raised in rabbits by use of Freund’s complete and incom-al. 1994) was subcloned into the expression vector
plete adjuvants as reported elsewhere for antiserapGEX-4T-2 (Pharmacia). In vitro mutagenesis was per-
against puriﬁed rat liver FBPase (Mizunuma and Ta-formed by use of the U.S.E. mutagenesis kit (Pharmacia)
shima 1986). Recombinant human liver FBPase was ex-and was based on the unique site elimination method
pressed and puriﬁed as reported elsewhere (Kikawa et(Deng and Nickoloff 1992). To carry the mutations,
al. 1995). The experimental protocol was approved byeach mutagenic primer was designed from a complemen-
the ethics-review committees for human and animal ex-tary sequence corresponding to the G164S and A177D
perimentation at Fukui Medical School.mutations. The selected primer was used to eliminate a
unique nonessential restriction-enzyme site in the plas-
mid, which subsequently served for selection of mutant Results
plasmids. Two mutagenic primers and one selection
Identiﬁcation of One Known and Four New Pointprimer for in vitro mutagenesis are listed in table 2. A
Mutationsmismatch repair–defective (mutS) host, E. coli BMH71-
18mut, was used for transformation in vitro mutagene- Mutation analysis was performed by use of samples
from 13 patients with FBPase deﬁciency (in 11 unrelatedsis. After digestion with the restriction enzymes, SmaI
and SalI, the expression vectors were ligated and trans- Japanese families). One previously characterized and
four novel mutations were identiﬁed in 16 of the 22formed. Constructs containing the normal and mutant
FBPase cDNA and the G164S, A177D, and chimeric alleles: one G-residue insertion in the cluster of four G’s
at positions of 957–960 in exon 7, designated ‘‘960/V325A mutations, were designated as ‘‘pGEXFBPN,’’
‘‘pGEXFBPG164S,’’ ‘‘pGEXFBPA177D,’’ and ‘‘pGEX- 961insG’’ (10 alleles); a GlyrSer substitution at codon
164 in exon 4 (G490GCrA490GC), designated ‘‘G164S’’FBPV325A,’’ respectively, and were overexpressed in E.
coli JM109 cells. (3 alleles), a ValrAla substitution at codon 325 in exon
7 (GT974GrGC974G), designated ‘‘V325A’’ (1 allele),
Puriﬁcation of the Mutant and Normal FBPase which harbored in one of the 3 alleles with the G164S
Overexpressed in E. coli mutation an AlarAsp substitution at codon 177 in exon
4 (GC530CrGA530C), designated ‘‘A177D’’ (1 allele);Mutant and normal FBPase proteins were overex-
pressed as fusion proteins with the C terminus of Sj26, and a Glu to stop at codon 30 in exon 1
(G88AGrT88AG), designated ‘‘E30X’’ (2 alleles). Nonea 26-kD glutathione S-transferase (E.C.2.5.1.18) en-
coded by the parasitic helminth Schistosoma japonicum of these ﬁve mutations were found at any of FBPase
cDNA samples from 40 healthy donors. Other six alleles(Smith and Johnson 1988). Fusion proteins were puri-
ﬁed from bacterial lysates by afﬁnity chromatography that harbored no mutation caused a loss or decrease of
FBPase enzyme activity in the coding region and in theusing glutathione Sepharose 4B contained in the gluta-
thione S-transferase puriﬁcation kit (Pharmacia). Cleav- exon/intron boundary. The genotype of each patient is
shown in table 3.age of proteins was achieved by use of a site-speciﬁc
protease, thrombin, whose recognition sequence is lo- The 960/961insG mutation was found in patients 1–
3, as homozygosity, and in patients 4a, 4b, 5a, 5b, 6,cated immediately upstream from the multiple cloning
site on pGEX plasmids. The puriﬁed mutant and normal and 7, as heterozygosity, by direct sequencing of PCR-
ampliﬁed genomic DNA of exon 7 (only data for pa-FBPase proteins were analyzed by SDS-PAGE to esti-
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tients 3 and 4a are shown in ﬁg. 1A, top and middle, The E30X mutation was detected in patient 8, as ho-
mozygosity, by direct sequencing of PCR-ampliﬁed ge-respectively). This mutation was conﬁrmed both by se-
quencing of subclones from cDNA and by direct se- nomic DNA of exon 1 (ﬁg. 1E, top). This mutation was
conﬁrmed on both alleles of this patient, by sequencingquencing of cDNA from cultured monocytes, except in
patient 2, from whom monocytes were not available for of subclones from PCR-ampliﬁed exon 1 of genomic
DNA. The remainder of genomic DNA, including exonscDNA analysis. The remainder of the genomic DNAs in
patients 1–3 were identical to the wild-type sequence. 1–7 and certain parts of the promoter area, were identi-
cal to that of the wild-type sequence.SSCP analysis of exon 7 from patients 1–3, 4a, 4b,
5a, 5b, 6, and 7 and from their family members also
RFLP Analysis for the G164S, A177D, and E30Xconﬁrmed homozygosity or heterozygosity of the 960/
Mutations961insG mutation. In patients 4a and 4b and their fa-
To conﬁrm the authenticities of the G164S, A177D,ther, the presence of another mutation in exon 7 was
and E30X mutations, restriction-enzyme analysis wassuggested on the basis of SSCP patterns different from
performed by use of PCR-ampliﬁed genomic DNA orthose of other patients or family members (ﬁg. 2).
cDNA from patients 4a, 4b, 5a, 5b, 6 and 7 and theirAnother new mutation in exon 7, the V325A muta-
family members. The G164S mutation created a newtion, was found in patients 4a and 4b and their father, as
AluI endonuclease restriction site, GGCTrAGCT. Inheterozygosity, by direct sequencing of PCR-ampliﬁed
the presence of this missense mutation as heterozygosity,genomic DNA (only data at the antisense strand for
the 281-bp PCR fragment was partially cleaved by AluI,patient 4a are shown in ﬁg. 1B, top). This mutation
into 151-bp and 130-bp fragments; in contrast, this 281-was conﬁrmed as belonging to the second mutant allele
bp fragment remained uncleaved in the absence ofdifferent from the one with the 960/961insG mutation,
G164S mutation (ﬁg. 3). The results of AluI digestionby sequencing of a subclone from PCR-ampliﬁed cDNA.
showed that patients 4a and 4b and their father andThe G164S mutation was found in patients 4a, 4b, 5a,
patients 5a, 5b, and 6 were heteroallelic for this muta-5b, and 6, as heterozygosity, by direct sequencing of
tion. Heterozygosity of this mutation in the father wasPCR-ampliﬁed genomic DNA. The G164S and V325A
conﬁrmed by direct sequencing of the 281-bp PCR frag-mutations were found to harbor the same second mutant
ment. The A177D mutation eliminated a NcoI endonu-alleles detected in patients 4a and 4b, by sequencing
clease restriction site, CCATGGrACATGG. In the pres-of a subclone from PCR-ampliﬁed cDNA. The G164S
ence of this missense mutation as heterozygosity, themutation was also conﬁrmed in the second mutant allele
281-bp PCR fragment was only partially cleaved byin patients 4a, 4b, 5a, 5b, and 6, by sequencing of sub-
NcoI, into 191-bp and 90-bp fragments; in contrast, thisclones from PCR-ampliﬁed cDNA (only data at the anti-
281-bp fragment was completely cleaved in the absencesense strand for patient 5a are shown in ﬁg. 1C, top).
of G164S mutation (ﬁg. 4). The results of NcoI digestionThe A177D mutation was detected in patient 7, as
showed that patient 7 and her father were heteroallelicheterozygosity, by direct sequencing of PCR-ampliﬁed
for this mutation. Heterozygosity of this mutation ingenomic DNA (data shown in ﬁg. 1D, top). This muta-
her father was conﬁrmed by direct sequencing of thetion was also conﬁrmed in the second mutant allele,
281-bp PCR fragment (data not shown). Finally, theby sequencing of subclones from PCR-ampliﬁed cDNA.
E30X mutation created a MaeI endonuclease restrictionBoth the remainder of cDNA in the coding region and
site, CGAGrCTAG. In the presence of this nonsensethe 3 UTRs in patients 4a, 4b, 5a, 5b, 6, and 7 were
identical to the those of the wild-type sequence. mutation, the 313-bp PCR fragment was cleaved by
Table 3
Genotypes of 13 Japanese Patients with FBPase Deﬁciency
Patient Allele 1 Allele 2 Codon Mutation Exon(s)
1 InsG960/961 InsG960/961 321/321 Stop 7/7
2 InsG960/961 InsG960/961 321/321 Stop 7/7
3 InsG960/961 InsG960/961 321/321 Stop 7/7
4a G490A/T974C InsG960/961 164 and 325/321 G164S and V325A/stop 4, 7/7
4b G490A/T974C InsG960/961 164 and 325/321 G164S and V325A/stop 4, 7/7
5a G490A InsG960/961 164/321 G164S/stop 4/7
5b G490A InsG960/961 164/321 G164S/stop 4/7
6 G490A InsG960/961 164/321 G164S/stop 4/7
7 C530A InsG960/961 177/321 A177D/stop 4/7
8 G88T G88T 30/30 E30X/E30X 1/1
9–11a (No mutation either in coding region or in exon/intron boundary)
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Figure 1 Nucleotide sequence of the PCR-ampliﬁed genomic fragment around the observed mutation in patients, and the corresponding
region in normal control. Exon 1-, 4-, or 7-speciﬁc genomic DNA fragments were ampliﬁed, and their nucleotide sequences were directly
determined. A, top, Nucleotide sequence of the sense strand (exon 7) in patient 3, around the homozygous 960/961insG that leads to a
frameshift and the formation of truncated enzyme protein. middle, Nucleotide sequence of the sense strand in patient 4a, around the heterozygous
960/961insG. The patient carried the 960/961insG mutation on her maternal chromosome, whereas the paternal chromosome carried the
490GrA transition (G164S missense mutation) and the 974TrC transition (V325A nonsense mutation). B, top, Nucleotide sequence of the
antisense strand in patient 4a, around the compound heterozygous 974TrC transition and the 960/961insG mutation (exon 7). C, top,
Nucleotide sequence of the antisense strand in patient 4a, around the 490GrA transition (exon 4; G164S missense mutation). D, top, Nucleotide
sequence of the sense strand in patient 7, around the 530CrA transversion (exon 4; A177D missense mutation). The patient carried the
530CrA transversion on her maternal chromosome, whereas the paternal chromosome carried the 960/961insG mutation. E, top, Nucleotide
sequence of the sense strand in patient 8, around the homozygous 88GrT transversion (exon 1; E30X nonsense mutation), which would lead
to premature termination of the translation product.
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Figure 2 Pedigrees and SSCP analysis of genomic DNA frag-
ments including part of exon 7 from patients and a control, which Figure 3 Pedigree of families 4 and 5 and patient 6, and detec-
includes the 960/961insG and V325A mutations. The homoallelic tion of the G164Smutation in a PCR fragment ampliﬁed from genomic
state for the 960/961insG mutation is shown in lanes 1–3 (patients DNA including exon 4 after digestion by AluI. The 281-bp fragment
1–3 are homoallelic for this mutation), by a single strand with the is partially cleaved into 151-bp and 131-bp fragments only in lanes
960/961insG mutation (indicated by the ‘‘G’’ and arrow on the left- 1–3 (representing, respectively, patients 4a and 4b and their father)
hand side of the gel). The heteroallelic states for the 960/961insG and and in lanes 7–9 (representing, respectively, patients 5a, 5b, and 6),
V325A mutations are shown in lanes 4–6 (marked with an asterisk indicating a heterozygous state for the G164S mutation. Lane M,
[*]) (patients 4a and 4b were compound heteroallelic for both the Molecular-weight marker PhiX174 digested by HaeIII. Lane C, Nor-
mutations, and their father was heteroallelic for the V325A mutation mal control sample.
only), by a single strand with the 960/961insG mutation (indicated
by the ‘‘G’’ and arrow on the left-hand side of the gel) and by a single
strand with V325A mutation (indicated by an asterisk with an arrow).
clone was comparable to that in human liver (9.8 { 0.8The heteroallelic state for the 960/961insG mutation only is shown
in lanes 7, 9, 10, 11, 12, 13, 14, 16, and 18 (representing, respectively, units/mg protein), as reported by El-Maghrabi et al.
the heteroallelic mother of patients 4a and 4b, their grandmother, (1993).
patients 5a, 5b, 6, two sisters of patient 7, patient 7, and the father
of patient 7), by a normal single strand (indicated by ‘‘N’’ and an
Discussionarrow, on the right-hand side of the gel) and by a single strand with
the 960/961insG mutation (indicated by ‘‘G’’ and an arrow on the
In the present study, we investigated 13 Japanese pa-right-hand side of the gel). The normoallelic state for these two muta-
tients with FBPase deﬁciency. The major ﬁnding of ourtions is conﬁrmed in lanes 8, 15, 17, and C (representing, respectively,
study was the identiﬁcation of four novel point muta-the grandmother of patients 4a and 4b, brother and mother of patient
7, and a normal healthy control). tions and a 960/961insG mutation in 16 of the 22 al-
leles—that is, an overall detection rate of 73%. Of the
MaeI into 176-bp and 137-bp fragments; in contrast,
this 313-bp fragment remained uncleaved in control
samples (ﬁg. 5). The results of MaeI digestion showed
that patient 8 was homoallelic for this mutation.
FBPase Activity of Mutant Proteins Overexpressed
in E. coli
The effects of the G164S, A177D, and chimeric
V325A mutations on FBPase activity were tested by in
vitro expression of the mutant cDNA construct overex-
pressed in E. coli. Overexpressed protein bands in both
SDS-PAGE andwestern blotting analyses were of similar
size (Ç37 kD) in all mutant, chimeric, and normal clones
(ﬁg. 6). FBPase activities in puriﬁed proteins were 0.1
Figure 4 Pedigree of family 7, and detection of A177D mutationand 0.2 units/mg protein in mutant clones with G164S
in a PCR fragment ampliﬁed from genomic DNA including exon 4and A177D mutations, respectively; in contrast, mean
after digestion by NcoI. The 281-bp fragment is partially cleaved into{ SD FBPase activities in puriﬁed proteins were 5.3
191-bp and 90-bp fragments only in lanes 4 and 5 (representing,{ 0.7 units/mg protein and 6.8 { 0.5 units/mg protein respectively, patient 7 and her father), indicating a heterozygous state
in the chimeric V325A mutant clone and the normal for the A177D mutation. Lane M, Molecular-weight marker PhiX174
digested by HaeIII. Lane C, Normal control sample.clone, respectively. The mean { SD value in the normal
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tients. However, the 960/961insG mutation may be
found in other ethnic groups, because the tendency for
insertional mutation sequence is supposedly common in
other ethnic groups. Conﬁrmation of our speculation
must await the results of molecular analysis of patients
with FBPase deﬁciency who are from other ethnic
groups.
The other two missense mutations, G164S and
A177D, resulted in the formation of FBPase protein with
negligible enzyme activity. The glycine at position 164
and the alanine at position 177 are both well conserved
Figure 5 Detection of the E30X mutation in a PCR fragment in FBPase enzymes of humans, pigs, and rats (El-Magh-ampliﬁed from genomic DNA including exon 1 after digestion by
rabi et al. 1988, 1993). Alanine is conserved even inMaeI. The 313-bp fragment is completely cleaved into 176-bp and
yeast (Roger et al. 1988), thus suggesting a critical role137-bp fragments, indicating a homozygous state for the E30X muta-
tion. Lane M, Molecular-weight marker PhiX174 digested by HaeIII. for these two amino acids in the structure of FBPase
Lane C, Normal control sample. protein. The G164S mutation is expected to result in
certain conformational changes, since the highly hydro-
philic serine substitutes the low-hydrophilic glycine.
Similarly, the A177D mutation substitutes the hy-four point mutations, the V325A mutation does not
seem to be responsible for FBPase deﬁciency, because drophobic alanine for the hydrophilic negatively
charged aspartic acid. The roles of these two amino acidsthe chimeric clone associated with this mutation showed
an almost normal FBPase activity. Alternatively, it could are also suggested by the three-dimensional structure
of mammalian FBPase, constructed by crystallographyrepresent a rare polymorphism, since this mutation was
not found in any of 40 normal healthy donors. The 960/ (Hengming et al. 1989). Eight-stranded b-sheets of
FBPase enzyme are thought to be responsible for com-961insG mutation (in 46% of the 22 alleles) was the
most common mutation (occurring in 7 of 11 families) munication between AMP and the active site of the en-
among Japanese patients with homozygous or heterozy-
gous FBPase deﬁciency. We have conﬁrmed recently that
such mutation results in the appearance of clinical mani-
festations of the disease that are due to overexpression
of FBPase enzyme protein without enzyme activity (Ki-
kawa et al. 1995). The high frequency of the 960/
961insG mutation in the present study may be explained
by the homogeneity of Japanese patients. A more plausi-
ble explanation is the peculiar DNA sequence around
the mutation site, which results in the induction of inser-
tional mutagenesis. Cooper and Krawczak (1991) pro-
posed two separate mechanisms to explain insertional
mutagenesis in human genes that causes genetic diseases
by inserting DNA fragments õ10 bp. The ﬁrst mecha-
nism involves slipped mispairing mediated by direct re-
peats or runs of identical bases, whereas the second
mechanism involves the templated misincorporation of
bases by secondary-structure intermediates whose for-
mation is facilitated by palindromic (inverted repeat) or Figure 6 A, Analysis of FBPase proteins by SDS-PAGE. B,
Analysis of FBPase proteins by western blotting. Expression plasmidsquasi-palindromic sequences. The insertion of one G
with normal (from liver) and mutant FBPase cDNA—pGEXFBPN,residue was found in the wild-type sequence of
pGEXFBPG164S, pGEXFBPA177D, and pGEXFBPV325A—wereTTG957GGG960TCCCCCGACGACG. The sequence of constructed. These FBPase proteins were expressed and puriﬁed as
G957GGG960 is a run of identical bases, and that of described in the text. Approximately 2.5 mg of puriﬁed protein was
G957GGG960TCCC CC forms a quasi-palindrome. Thus, applied in each lane for SDS-PAGE analysis and western blotting
analysis. Lane 1, Normal FBPase protein from the expression plas-structures consistent with both mechanisms proposed
mid pGEXFBPN. Lanes 2–4, Mutant FBPase protein fromby Cooper and Krawczak (1991) exist in the sequence
pGEXFBPG164S, pGEXFBPA177D, and pGEXFBPV325A, respec-containing the insertion of one G residue. Until now,
tively. Lane M, Marker standards with sizes (in kD) shown. The
genetic mutations responsible for FBPase deﬁciency have arrow indicates the location of puriﬁed proteins. Overexpressed pro-
been examined by our group and El-Maghrabi and co- tein bands in both SDS-PAGE and western blotting analyses are of
a similar size (Ç37 kD) in all mutant, chimeric, and normal clones.workers and have been described only in Japanese pa-
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zyme, and the inhibition of FBPase activity by AMP associated with hypoglycemia, at least in patients 1 and
9. In these two patients, the clinical condition did notoccurs at the allosteric site (Liang et al. 1993). The gly-
cine at position 164 and alanine at position 177 belong improve even after successful correction of hypoglyce-
mia. At ﬁrst, the latter patient was diagnosed as havingto the b-strands B5 and B6, respectively (Liang et al.
1993). Theoretically, both the G164S and A177D muta- died of sudden unexpected infant death but later, on
the basis of an autopsied liver sample, was properlytions may abolish enzyme activity by affecting commu-
nication between AMP and the active site of the enzyme, diagnosed to have had deﬁcient FBPase activity. Thus,
it is highly likely that the use of glycerol aggravated thealthough this hypothesis remains unconﬁrmed by crys-
tallographic analysis. Finally, we have not expressed the clinical condition of these two patients. Carrier detec-
tion is, therefore, important as a means of providingenzymatic activity of the E30X mutation. This nonsense
mutation is expected to result in premature termination appropriate postnatal care for FBPase-deﬁcient babies.
The use of molecular tests in the present study allowedresulting in approximately one-twelfth the length of nor-
mal FBPase protein, lacking almost all of the crucial carrier detection in eight families of 10 patients—al-
though, unfortunately, not in the family of patient 9—amino acid side chains for the active and allosteric sites
(Hengming et al. 1989; Liang et al. 1993). by identifying mutations in the FBPase genomic gene.
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